Norden Group LLC Acquires 3,090 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Norden Group LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 54.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,725 shares of the biopharmaceutical company’s stock after purchasing an additional 3,090 shares during the period. Norden Group LLC’s holdings in Halozyme Therapeutics were worth $322,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Advisors Asset Management Inc. increased its holdings in shares of Halozyme Therapeutics by 0.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock valued at $1,742,000 after acquiring an additional 287 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Halozyme Therapeutics by 2.6% during the 3rd quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 308 shares during the period. Commonwealth Equity Services LLC grew its stake in Halozyme Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock valued at $619,000 after buying an additional 347 shares during the last quarter. Truist Financial Corp raised its holdings in Halozyme Therapeutics by 0.6% in the 4th quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock worth $3,793,000 after acquiring an additional 563 shares during the period. Finally, Alliance Wealth Advisors LLC UT lifted its position in Halozyme Therapeutics by 7.4% during the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 8,389 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 581 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Up 3.1 %

Shares of HALO stock opened at $39.30 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $29.85 and a one year high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The stock has a fifty day moving average price of $40.00 and a 200 day moving average price of $37.86. The stock has a market cap of $4.99 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 0.44 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Analysts predict that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Analyst Ratings Changes

HALO has been the topic of a number of recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. Benchmark restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Finally, TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now directly owns 156,558 shares in the company, valued at $6,519,075.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock worth $1,196,800 in the last 90 days. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.